GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives
This article was originally published in PharmAsia News
Executive Summary
TOKYO - GlaxoSmithKline is making rounds to draw big pharma partners to its patent pool and open laboratory for neglected disease research, but questions linger over what will happen if precompetitive collaboration produces technology or compounds that have use outside of the world's poorest countries